News >

Expert Shares Upfront Sequencing Strategies in mRCC

Gina Columbus
Published: Thursday, Jul 05, 2018

Sumanta Kumar Pal, MD

Sumanta Kumar Pal, MD
Even with 2 recent FDA approvals in the frontline setting for patients with metastatic renal cell carcinoma (mRCC), an ongoing clinical trial exploring combination therapy with a multikinase inhibitor and an anti–PD-L1 agent could be yet another path forward, according to Sumanta Kumar Pal, MD.

State of the Science Summit™ on Genitourinary Cancers, Pal, a medical oncologist at City of Hope, shed light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

OncLive: What did you highlight during your discussion on first-line treatment in kidney cancer?

Pal: A lot of discussion hinged on some of the newer data with bevacizumab (Avastin )and atezolizumab in the IMmotion151 trial. We are really seeing some outstanding efficacy with this combination of agents—supporting this premise of using a VEGF inhibitor with an immuno-oncology agent. We discussed the evolving data sets that combine VEGF inhibitors and immunotherapy-based agents, and I also alluded to some of the trials that I’m really excited about. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication